IsoPlexis joins MediMergent, CCBD for COVID-19 study

2020 06 17 20 35 0417 Covid 19 Antibody 400

IsoPlexis on Tuesday said it is joining forces with MediMergent and the Center for Cancer and Blood Disorders (CCBD), an American Oncology Network partner, to utilize IsoPlexis’ single-cell proteomic technology in a study assessing an antibody combination for preventing COVID-19 infection in immunocompromised cancer patients.

The large multisite study will focus on the functionality of immune cells and their role in prevention of breakthrough COVID-19 infections in immunocompromised patients following administration of AstraZeneca's AZD7442 IM or IV antibody combination.

IsoPlexis said that its single-cell proteomics technology will enable researchers to uncover the T-cell activity and mechanisms associated with breakthrough COVID-19 infections in these patients.

Page 1 of 1